<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511159</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1464</org_study_id>
    <nct_id>NCT01511159</nct_id>
  </id_info>
  <brief_title>Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers</brief_title>
  <official_title>A Single-Centre, Open-Label, Five-Period Crossover Trial In Healthy Male Volunteers Investigating the Relative Bioavailability of NNC 90-1170 By Pulmonary Administration Compared To A Subcutaneous Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to determine the relative
      bioavailability of NNC 90-1170 (liraglutide) when inhaled compared to NNC 90-1170 when
      injected under the skin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">December 2001</completion_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of the areas under the plasma NN 90-1170 curves</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The maximum concentration (Cmax)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to maximum concentration (tmax)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NNC 90-1170, initial dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC 90-1170</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC 90-1170, final dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data</description>
    <arm_group_label>NNC 90-1170, initial dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose by inhalation. Progression to open-label trial part will be based on safety data</description>
    <arm_group_label>NNC 90-1170, initial dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order</description>
    <arm_group_label>NNC 90-1170</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order</description>
    <arm_group_label>NNC 90-1170</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin human</intervention_name>
    <description>Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order</description>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin human</intervention_name>
    <description>Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order</description>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation</description>
    <arm_group_label>NNC 90-1170, final dose</arm_group_label>
    <other_name>NNC 90-1170</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No clinically important abnormal physical findings

          -  No clinically relevant abnormalities in the results of laboratory screening evaluation

          -  Normal (or abnormal but not clinically significant) ECG (electrocardiogram)

          -  Normal (or abnormal but not clinically significant) blood pressure and heart rate

          -  Body Mass Index (BMI) between 20-30 kg/m^2 or outwith range but not clinically
             significant

          -  Non-smoker

          -  Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1) at least
             85% of predicted normal for age, gender and height

          -  FVC ratio at least 75% of predicted normal for age, gender and height

        Exclusion Criteria:

          -  A clinically significant illness or infection requiring treatment within the last two
             months

          -  Any infection involving the respiratory system or adverse event that may, in the
             opinion of the principal investigator, interfere with blood glucose homeostasis

          -  Subjects with first and/or second degree relative(s) with diabetes mellitus

          -  Donation or loss of greater than 500 ml of blood in the period 0-12 weeks before trial
             entry

          -  Alcohol use in excess of 28 units of alcohol per week. A unit of alcohol is equivalent
             to half a pint of average strength beer, a glass (125 ml) of wine or a pub measure (25
             ml) of spirits, sherry or port

          -  Current addiction to alcohol or substances of abuse

          -  Females

          -  Presence of hepatitis B surface antigen, hepatitis C antibody or HIV (human
             immunodeficiency virus) 1 or 2 antibodies
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tranent</city>
        <zip>EH33 2NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2012</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

